Provided by Tiger Fintech (Singapore) Pte. Ltd.

Takeda Pharmaceutical Co Ltd

15.14
+0.12000.80%
Post-market: 15.140.00000.00%18:42 EDT
Volume:1.27M
Turnover:19.28M
Market Cap:46.31B
PE:36.57
High:15.17
Open:14.97
Low:14.97
Close:15.02
Loading ...

Takeda Canada says Health Canada expands marketing authorization for HyQvia

TIPRANKS
·
Yesterday

Mirum Pharmaceuticals Says Livmarli Approved in Japan for Pruritus

MT Newswires Live
·
Yesterday

ACIU Stock Crashes 18.3% in a Month: Buy, Sell or Hold?

Zacks
·
25 Mar

Is Takeda Pharmaceutical Co. (TAK) a Great Value Stock Right Now?

Zacks
·
19 Mar

TAK or DSNKY: Which Is the Better Value Stock Right Now?

Zacks
·
14 Mar

Will ADMA Biologics Stock Continue Its Momentum in 2025?

Zacks
·
14 Mar

Takeda-Protagonist Therapeutics Partnered Investigational Drug Hits Primary Goal In Late-Stage Study In Patients With Type Of Blood Cancer

Benzinga
·
04 Mar

Should Value Investors Buy Takeda Pharmaceutical Co. (TAK) Stock?

Zacks
·
03 Mar

Protagonist, Takeda Say Phase 3 Study of Rusfertide Meets Endpoints in Polycythemia Vera

MT Newswires Live
·
03 Mar

Protagonist and Takeda Announce Positive Topline Results from Phase 3 VERIFY Study of Rusfertide in Patients with Polycythemia Vera

Business Wire
·
03 Mar

AbbVie Receives Positive CHMP Opinion for Upadacitinib (RINVOQ®) for the Treatment of Adults with Giant Cell Arteritis

PR Newswire
·
28 Feb

Is Takeda Pharmaceutical Company Limited (TAK) the Best Low Price Pharma Stock to Invest In Right Now?

Insider Monkey
·
27 Feb

Takeda announces EMA approval for Takhzyro two mL pre-filled pen option

TIPRANKS
·
24 Feb

Takeda Secures EMA Approval for Additional Injection Option for Hereditary Angioedema Drug

MT Newswires Live
·
24 Feb

The European Medicines Agency (EMA) Has Approved an Additional Subcutaneous Administration Option for TAKHZYRO® (lanadelumab) for Patients Aged 12 Years and Above with Recurrent Attacks of Hereditary Angioedema (HAE)

PR Newswire
·
24 Feb

TAK vs. DSNKY: Which Stock Is the Better Value Option?

Zacks
·
18 Feb